Literature DB >> 20890105

Evolutionary dynamics of two related malignant plasma cell lines.

David Dingli1, Bonnie K Arendt, Zeljko Bajzer, Diane F Jelinek.   

Abstract

Cancer is the consequence of sequential acquisition of mutations within somatic cells. Mutations alter the relative reproductive fitness of cells, enabling the population to evolve in time as a consequence of selection. Cancer therapy itself can select for or against specific subclones. Given the large population of tumor cells, subclones inevitably emerge and their fate will depend on the evolutionary dynamics that define the interactions between such clones. Using a combination of in vitro studies and mathematical modeling, we describe the dynamic behavior of two cell lines isolated from the same patient at different time points of disease progression and show how the two clones relate to one another. We provide evidence that the two clones coexisted at the time of initial presentation. The dominant clone presented with biopsy proven cardiac AL amyloidosis. Initial therapy selected for the second clone that expanded leading to a change in the diagnosis to multiple myeloma. The evolutionary dynamics relating the two cell lines are discussed and a hypothesis is generated in regard to the mechanism of one of the phenotypic characteristics that is shared by these two cell lines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890105      PMCID: PMC3047803          DOI: 10.4161/cc.9.18.13047

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  26 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  DNA replication fidelity.

Authors:  T A Kunkel; K Bebenek
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

3.  Imatinib: can one outwit chronic myeloid leukemia?

Authors:  Lucio Luzzatto; Francesco Frassoni; Junia V Melo
Journal:  Haematologica       Date:  2002-09       Impact factor: 9.941

4.  Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.

Authors:  Lucio Luzzatto; Junia V Melo
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 5.  Mechanisms of myeloma cell growth control.

Authors:  D F Jelinek
Journal:  Hematol Oncol Clin North Am       Date:  1999-12       Impact factor: 3.722

6.  Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.

Authors:  J D French; R C Tschumper; D F Jelinek
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

Review 7.  STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

Authors:  M V Blagosklonny
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

8.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

9.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Authors:  Catherine Roche-Lestienne; Valerie Soenen-Cornu; Nathalie Grardel-Duflos; Jean-Luc Laï; Nathalie Philippe; Thierry Facon; Pierre Fenaux; Claude Preudhomme
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 10.  Genetic instability is not a requirement for tumor development.

Authors:  Walter Bodmer; Jason H Bielas; Robert A Beckman
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

View more
  2 in total

Review 1.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

2.  Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Authors:  Cameron S Fraser; Johan K E Spetz; Xingping Qin; Adam Presser; Jonathan Choiniere; Chendi Li; Stacey Yu; Frances Blevins; Aaron N Hata; Jeffrey W Miller; Gary A Bradshaw; Marian Kalocsay; Vaishali Sanchorawala; Shayna Sarosiek; Kristopher A Sarosiek
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.